HRS2300
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 19, 2024
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=13 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=345 ➔ 13 | Recruiting ➔ Terminated; Sponsor R&D strategy adjustment
Enrollment change • Metastases • Monotherapy • Trial termination • Oncology
November 02, 2021
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1; N=345; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Monotherapy • Oncology • Solid Tumor
September 17, 2021
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1; N=345; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • Monotherapy • New P1 trial • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1